Alexza pulls plug on pain drug and one-third of employees(0)
Alexza Pharmaceuticals announced the elimination fo 52 employees, or a third of its staff, last week the same day it reported the cancellation with Endo Pharmaceticals of a joint development agreement for Alexza’s AZ-300 drug candidate designed to treat abnormal flare-ups of pain in addition to the chronic pain suffered by cancer patients and others.
Endo originally paid Alexza a $10 million Read the rest of this entry »
Subscribe via RSS all feeds